GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report) rose 4% on Wednesday. The company traded as high as $55.91 and last traded at $55.80. 5,137,139 shares traded hands during trading, an increase of 10,480% from the average daily volume of 48,553 shares. The stock had previously closed at $53.63.
GENMAB A/S/S Stock Up 4.0%
The company has a fifty day simple moving average of $39.73 and a 200-day simple moving average of $31.24.
Hedge Funds Weigh In On GENMAB A/S/S
A hedge fund recently bought a new stake in GENMAB A/S/S stock. Madison Asset Management LLC acquired a new stake in GENMAB A/S/S (OTCMKTS:GMXAY – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 70,781 shares of the company’s stock, valued at approximately $1,944,000.
About GENMAB A/S/S
Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing, and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to develop therapies designed to engage the immune system and target disease-related mechanisms. Genmab’s marketed and partnered products include DARZALEX (daratumumab) for certain blood cancers, EPKINLY (epcoritamab) for certain types of B-cell lymphoma, and Tivdak (tisotumab vedotin) for cervical cancer.
Further Reading
- Five stocks we like better than GENMAB A/S/S
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
